
With its expanded approval of Lumizyme (alglucosidase alfa) to treat all Pompe disease patients, regardless of age or time of disease onset, the FDA has eliminated the Risk Evaluation and Mitigation Strategy program that restricted the drug's use to those aged 8 years or older with late-onset disease.


































































































































































































































